Celon Pharma S.A. (WSE:CLN)

Poland flag Poland · Delayed Price · Currency is PLN
24.00
-0.15 (-0.62%)
Feb 13, 2025, 5:00 PM CET
61.07%
Market Cap 1.29B
Revenue (ttm) 209.54M
Net Income (ttm) 18.51M
Shares Out 53.86M
EPS (ttm) 0.35
PE Ratio 68.68
Forward PE 23.48
Dividend 0.08 (0.33%)
Ex-Dividend Date Jun 27, 2024
Volume 36,287
Average Volume 25,749
Open 24.15
Previous Close 24.15
Day's Range 23.90 - 24.45
52-Week Range 14.62 - 32.90
Beta 0.82
RSI 40.48
Earnings Date Apr 16, 2025

About Celon Pharma

Celon Pharma S.A., an integrated pharmaceutical company, engages in the research, manufacture, and marketing of pharmaceutical products and preparations. It offers drugs to treat cancers, neurological diseases, diabetes, and other metabolic disorders. The company was founded in 2002 and is based in Lomianki, Poland. Celon Pharma S.A. operates as a subsidiary of Glatton Sp. z o.o. [Read more]

Sector Healthcare
Founded 2002
Employees 515
Stock Exchange Warsaw Stock Exchange
Ticker Symbol CLN
Full Company Profile

Financial Performance

In 2023, Celon Pharma's revenue was 213.92 million, an increase of 10.33% compared to the previous year's 193.89 million. Losses were -28.12 million, -28.40% less than in 2022.

Financial Statements

News

There is no news available yet.